Public companyCompany profile · informational
CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company that co-developed Casgevy with Vertex. Its clinical pipeline includes in vivo editing programs for cardiovascular targets and allogeneic CAR-T cell therapies being tested in cancer and autoimmune disease.
Verified highlights each with its source
- Company reported (Aug. 3, 2026) that the FDA approved Casgevy for children 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia.
Source: globenewswire.com ↗ - Phase 1a data for in vivo ANGPTL3 editing candidate CTX310, presented at ESC Congress 2026 (Aug. 28, 2026), showed sustained lipid lowering through one year (company release).
Source: ir.crisprtx.com ↗ - Allogeneic CAR-T candidate CTX112 is in Phase 1 trials in autoimmune diseases including lupus and systemic sclerosis, and Phase 1/2 in B-cell malignancies (Q2 2026 update).
Source: ir.crisprtx.com ↗
Sources
- ir.crisprtx.comir.crisprtx.com
- globenewswire.comglobenewswire.com
Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.
Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.
